Charles River Laboratories International, Inc.

NYSE:CRL

Medical - Diagnostics & Research

Healthcare
$333.25 -1.33%

-$2.45 today

Market cap
$15.97B
Beta
1.45
P/E (TTM)
-48.3
EPS (TTM)
-$3.77
52W Low $144.26High $228.88

Volume 0.52M

Average 0.86M

CRL Sales of Investments

Cash received from selling or redeeming investments.

Charles River Laboratories International, Inc.NYSE: CRL

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments growth accelerates

Q2 FY2026 sales of investments of $8.14M rose 1514.5% year over year, ahead of the -42.6% change in trailing-twelve-month sales of investments. Sequentially, it rose 178.5% from the prior quarter. Over 3 fiscal years it compounded at +26.0% a year.

Context

  • Sales of investments amounted to 0.2% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1514.5% holds above the trailing-twelve-month pace of -42.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$8.14M+178.5% QoQ
Last fiscal yearDec 2025
$9.1M-78.2% YoY
LTMJun 2026
$18.06M-42.6% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1514.5%——
1 year-78.2%——
3-year CAGR+26.0%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
9.1M USD
Year-over-year change
-78.2%
4-year CAGR
+8.6%

Sales of Investments vs competitors

How CRL compares with its peers on the latest reported figures

  • CRL's LTM Jun 2026 sales of investments of $18.06M is the largest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of -42.6% is the lowest of 2, against a peer median of +19678.1%.
  • Sales of investments amounts to 0.5% of revenue for CRL, versus a peer median of 0.0%.
CRL Competitors Peer median
Sales of Investments for CRL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRLCharles River Laboratories International, Inc.LTM Jun 2026$18.06M -42.6%+26.0%0.5%
ICLRICON Public Limited CompanyLTM Jun 2026$15.34M +19678.1%+56.2%0.2%
MEDPMedpace Holdings, Inc.LTM Sep 2026$0 ——0.0%
CERTCertara, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding CRL) $0+19678.1%+56.2%0.0%

Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income398.84M492.61M480.37M25.29M(142.16M)
Depreciation & Amortization265.54M303.87M314.12M361.74M403.31M
Deferred Income Tax(24.01M)(35.88M)(50.9M)(67.43M)(75.29M)
Stock-Based Compensation71.47M73.62M72.05M69.89M71.08M
Change in Working Capital42.94M(152.55M)(102.38M)(30.33M)14.08M
Accounts Receivables(26.63M)(150.57M)(33.43M)21.61M35.74M
Inventory(25.16M)(78.52M)(62.3M)16.8M(48.78M)
Accounts Payables44.9M(2.65M)(20.43M)(14.27M)2.87M
Other Working Capital49.83M79.19M13.78M(54.47M)24.25M
Other Non-Cash Items6.01M(62.02M)(29.36M)375.41M466.63M
Operating Cash Flow760.8M619.64M683.9M734.58M737.65M
Capital Expenditures(228.77M)(324.73M)(318.53M)(232.97M)(219.15M)
Acquisitions (Net)(1.17B)(120.12M)(194.79M)(5.48M)17.44M
Purchases of Investments(45.56M)(158.27M)(54.22M)(52.88M)(20.08M)
Sales of Investments6.53M4.55M6.67M41.69M9.1M
Other Investing Activities264K(9.35M)(2.29M)4.55M3.36M
Investing Cash Flow(1.44B)(607.92M)(563.16M)(245.09M)(209.32M)
Debt Repayment669.98M19.79M(75.32M)(412.19M)(121.78M)
Common Stock Issued0000714K
Common Stock Repurchased(40.71M)(38.65M)(24.16M)(119.18M)(360.67M)
Dividends Paid00000
Other Financing Activities43.32M(23.54M)13.96M(19.56M)(54.98M)
Financing Cash Flow672.6M(42.4M)(85.52M)(550.93M)(536.73M)
Effect of Forex Changes17.73M25.58M8.04M(17.47M)18.83M
Net Change in Cash13.2M(5.1M)43.27M(78.91M)10.43M
Free Cash Flow532.03M294.91M365.37M501.61M518.49M

Charles River Laboratories International, Inc.

NYSE:CRL

Intrinsic Alpha fair value

Locked

Current Price

$333.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.